---
title: "Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Heterogeneity of treatment effect"
description: "Formulary evidence on Envudeucitinib (ESK-001, FTP-637) in Moderate-to-severe plaque psoriasis: Heterogeneity of treatment effect. Topics: Guideline recommendation to select systemic therapy by comorbidity and individual patient factors; Comorbidity-guided selection: inflammatory bowel disease, diabetes, cancer history, and latent tuberculosis; Conditions that make a biologic class less suitable: decision aid; Agent selection by comorbidity, special population, and phenotype: U.S. reviews; 11 further topics. 15 evidence topics quoted from 23 sources."
canonical: "https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/product-information-and-disease-description/heterogeneity-of-treatment-effect"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Heterogeneity of treatment effect

<a id="heading-2.2.2.3"></a>

## 2.2.2.3 Heterogeneity of Treatment Effect

<a id="topic-2.2.2.3-1"></a>

### Guideline recommendation to select systemic therapy by comorbidity and individual patient factors

> “We recommend taking into account efficacy (see Figure 1, Figure 2, and summary of the Cochrane Review), safety (see drug chapters), comorbidities (see Table 1 and Table 2 in publication Part 2, and respective chapters in the long version), and individual patient factors when choosing a systemic treatment for moderate to severe psoriasis.”
> “Accordingly, individual recommendation strengths arise individually from the examination of each patient, taking the factors effectiveness, safety, comorbidity, and other individual patient factors into account.”

Source: [Nast et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12800871/)

<a id="topic-2.2.2.3-2"></a>

### Comorbidity-guided selection: inflammatory bowel disease, diabetes, cancer history, and latent tuberculosis

> “In patients with psoriasis and IBD, we recommend preferentially using approved targeted therapies with documented efficacy in these conditions:”
> “We suggest against the use of IL17 inhibitors in patients with inflammatory bowel disease.”
> “If alternative treatments are available, we suggest prescribing alternatives to MTX in patients with type 2 diabetes (with concomitant metabolic syndrome and/or signs of liver damage).”
> “For patients in remission of cancer for more than 5 years, we recommend selecting the most appropriate option for psoriasis treatment independent of the cancer.”
> “For patients with latent TB infection, we recommend choosing one of the following options:”
> “acitretin, apremilast, ciclosporin, dimethyl fumarate, MTX, or phototherapy.”
> “We suggest against the use of deucravacitinib”
> “in patients with latent TB infections unless there are no other suitable treatment options.”
> “Due to lack of data concerning the reactivation risk”

Source: [Nast et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12875186/)

<a id="topic-2.2.2.3-3"></a>

### Conditions that make a biologic class less suitable: decision aid

> “What are some of the conditions that would make your doctor hesitant about giving you the treatment?”

Source: [Smith et al. (2024a)](https://academic.oup.com/bjd/article/190/2/270/7280929)

| Biologic class | Conditions listed in the decision aid |
| --- | --- |
| TNF inhibitors (adalimumab, certolizumab pegol, etanercept, infliximab) | “Moderate or severe heart failure, multiple sclerosis (or other conditions affecting the nerves)” |
| IL-12/23 inhibitor (ustekinumab) | “No particular condition” |
| IL-17 inhibitors (bimekizumab, brodalumab, ixekizumab, secukinumab) | “Inflammatory bowel disease (e.g. Crohn disease or ulcerative colitis), recurrent candida infection (i.e. thrush)” |

Source: [Smith et al. (2024a)](https://academic.oup.com/bjd/article/190/2/270/7280929)

<a id="topic-2.2.2.3-4"></a>

### Agent selection by comorbidity, special population, and phenotype: U.S. reviews

> “Selection of the appropriate treatment modality has evolved substantially with the rapid expansion of available options that can be individualized based on patients' comorbidity profiles, extent of disease, prior therapeutic response, and treatment preferences.”
> “This first article of a two-part series focuses on selecting systemic therapy for PsO patients with specific inflammatory comorbidities or a history of malignancy.”

Source: [Pasumarthi et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42896634/)

> “Choosing systemic therapy for psoriasis remains challenging in populations underrepresented in clinical trials, including pregnant and pediatric patients, patients with chronic infections, and those with difficult-to-treat phenotypes.”
> “Emphasis is placed on balancing efficacy, safety, monitoring burden, infection/reactivation risk, reproductive considerations, and disease phenotype.”

Source: [Karpoff et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42913858/)

<a id="topic-2.2.2.3-5"></a>

### Body weight: overweight and early loss of biologic efficacy in severe psoriasis

> “Among the 87 patients (mean [SD] age, 42.2 [12.5] years; 24 female patients and 63 male patients) included in the study, 16 (18.4%) had to switch to other biologics because of an early loss of therapeutic efficacy.”
> “Having overweight (body mass index, >25) was the only clinically relevant factor (odds ratio, 17.3; 95% CI, 3.2-434.6; P = .009).”

Source: [Kim et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11966480/)

<a id="topic-2.2.2.3-6"></a>

### Body weight: exposure and dosing statements in biologic labels

> “In subjects weighing more than 100 kg, 45 mg was also shown to be efficacious. However, 90 mg resulted in greater efficacy in these subjects”

Source: [Janssen STELARA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125261s173lbl.pdf)

> “Body Weight: The average plasma concentration in adult subjects weighing ≥120 kg was predicted to be at least 30% lower than those weighing < 120 kg (median of 87 kg)”

Source: [UCB BIMZELX prescribing information (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761151s010lbl.pdf)

> “Risankizumab-rzaa clearance and volume of distribution increase and plasma concentrations decrease as body weight increases; however, no dose adjustment is recommended based on body weight in adult patients.”

Source: [AbbVie SKYRIZI prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761105s053lbl.pdf)

<a id="topic-2.2.2.3-7"></a>

### Response across age, sex, race, body weight, baseline severity, and prior therapy subgroups: oral agent labels

> “Examination of age, gender, race, body weight, baseline disease severity, and prior systemic therapy did not identify differences in response to SOTYKTU at Week 16 among these subgroups.”

Source: [Bristol Myers Squibb SOTYKTU prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/214958s006sdn685lbl.pdf)

> “An examination of age, gender, race, body weight, baseline disease severity, and previous treatment with systemic or biologic agents did not identify differences in response to ICOTYDE among these subgroups.”

Source: [Janssen ICOTYDE prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220149Orig1s000lbl.pdf)

<a id="topic-2.2.2.3-8"></a>

### Response across age, sex, race, body weight, and prior therapy subgroups: IL-17 and IL-23 inhibitor labels

> “Examination of age, gender, race, body weight, baseline PASI score and previous treatment with systemic or biologic agents did not identify differences in response to SKYRIZI among these subgroups at Week 16.”

Source: [AbbVie SKYRIZI prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761105s053lbl.pdf)

> “Examination of age, gender, race, body weight, and previous treatment with systemic or biologic agents did not identify differences in response to TREMFYA among these subgroups.”

Source: [Janssen TREMFYA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761061s034lbl.pdf)

> “Examination of age, gender, race, body weight, and previous treatment with a biologic did not identify differences in response to TALTZ among these subgroups at Week 12.”

Source: [Eli Lilly TALTZ prescribing information (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/125521s032lbl.pdf)

> “Examination of age, gender, race, baseline IGA score and previous treatment with systemic or biologic agents did not identify differences in response to BIMZELX among these subgroups at Week 16.”

Source: [UCB BIMZELX prescribing information (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761151s010lbl.pdf)

<a id="topic-2.2.2.3-9"></a>

### Bimekizumab PASI 100 through 3 years by age, sex, weight, disease duration, severity, nail involvement, and prior biologic exposure

> “Subgroups of patients with moderate to severe plaque psoriasis were defined by age, sex, weight, disease duration, disease severity, nail involvement (modified Nail Psoriasis Severity Index > 0), and prior biologic exposure, at baseline.”
> “Among patients who received bimekizumab continuously for 3 years (N = 1107), PASI 100 response rates remained consistent across age (68.6% [40 to < 65 years]–73.7% [≥ 65 years]), sex (69.6% [male]–71.4% [female]), weight (63.4% [≥ 103.9 kg]–75.5% [< 74.3 kg]), disease duration (65.5% [≤ 5 years]–71.1% [> 20 years]), disease severity (67.7% [PASI 12 to < 15]–71.1% [PASI ≥ 20]), nail involvement (69.1% [yes]/71.3% [no]), and prior biologic exposure (71.7% [yes]/69.1% [no]; prior anti-TNF exposure 67.6% [yes]/70.6% [no]) subgroups; 95% CIs overlapped in all instances, indicating no meaningful differences between subgroups.”

Source: [Strober et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12619882/)

<a id="topic-2.2.2.3-10"></a>

### Prior biologic or apremilast exposure: deucravacitinib real-world response through 52 and 104 weeks

> “Among the total 110 patients, 71 were apremilast‐naïve and 39 were apremilast‐experienced, while 95 were biologic‐naive and 15 were biologic‐experienced (Table 1).”
> “Both in biologic naive and experienced patients, mean PASI scores continued to decrease from week 0 to week 52; however, the magnitude of decrease appeared higher in biologic‐naive patients: from 15.53 to 1.30 in biologic‐naive patients (91.6% reduction) versus from 7.78 to 3.30 (57.6% reduction) in biologic‐experienced patients.”

Source: [Hagino et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11975169/)

> “We studied 131 patients with moderate-to-severe psoriasis who received deucravacitinib 6 mg/day.”
> “Week 104 achieving PASI 100 and absolute PASI ≤ 1 were higher in apremilast-naïve patients (15.4% and 53.8%) than in apremilast-experienced patients (0% and 25%, respectively).”
> “Week 104 achieving PASI 75, PASI 90, PASI 100, and absolute PASI ≤ 1 were higher in biologic-naïve patients (84.6%, 57.7%, 15.4%, and 53.8%) than in biologic-experienced patients (25%, 25%, 0%, and 25%, respectively).”

Source: [Ishihara et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41657209/)

<a id="topic-2.2.2.3-11"></a>

### Prior apremilast nonresponse: deucravacitinib response in POETYK PSO-1 and PSO-2 through week 52

> “Of 168 (PSO-1) and 254 (PSO-2) patients randomized to apremilast, 54 (32.1% [PSO-1]) and 111 (43.7% [PSO-2]) did not achieve PASI 50 (PSO-1) and PASI 75 (PSO-2) at Week 24 and were switched to deucravacitinib.”
> “PASI 75 response rates improved from 0% at Week 24 to 46.3% (PSO-1) and 42.3% (PSO-2) at Week 52.”

Source: [Armstrong et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12873009/)

<a id="topic-2.2.2.3-12"></a>

### Prior systemic treatment status and the network meta-analysis

> “Indeed, response to biologics is different depending on treatment status (systemic‐naïve or not).”
> “However, due to the limited number of studies available for some specific comparisons, subgroup analyses and meta‐regressions were not possible.”
> “More randomised trials directly comparing active agents are needed, and these should include systematic subgroup analyses (sex, age, ethnicity, comorbidities, psoriatic arthritis).”

Source: [Sbidian et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12327466/)

<a id="topic-2.2.2.3-13"></a>

### Asian populations: deucravacitinib network meta-analysis estimates

> “Evidence suggests the comparative efficacy of systemic therapies may be different in Asian versus White patients.”
> “The estimated PASI 75 and 90 (95% credible interval) response rates for deucravacitinib were estimated to be 66% (49%–80%) and 40% (24%–58%) in Asian populations, notably higher than placebo (6% [4%–9%] and 1% [0.8–2%]) and apremilast (24% [12%–40%] and 9% [4%–20%]).”
> “No statistically significant difference was observed in PASI 75 and 90 responses between deucravacitinib and adalimumab, certolizumab pegol, infliximab, ustekinumab, and tildrakizumab.”

Source: [Tsai et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11624152/)

<a id="topic-2.2.2.3-14"></a>

### Japanese participants in POETYK PSO-1: week 16 and week 24 PASI 75

> “This report describes efficacy and safety in Japanese patients from this study (N = 66) who were randomly assigned to treatment with deucravacitinib 6 mg once daily (n = 32), placebo (n = 17), or apremilast 30 mg twice daily (n = 17).”
> “The proportion of Japanese patients achieving ≥75% reduction from baseline in PASI (PASI 75) score was numerically higher with deucravacitinib versus placebo and apremilast at Week 16 (78.1% vs. 11.8% and 23.5%, respectively) and versus apremilast at Week 24 (78.1% vs. 29.4%).”
> “The efficacy and safety of deucravacitinib in Japanese patients was consistent with those in the global population in POETYK PSO-1.”

Source: [Imafuku et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36882942/)

<a id="topic-2.2.2.3-15"></a>

### Prespecified efficacy and safety subgroups in the envudeucitinib phase 2 statistical analysis plan

> “The following subgroups may be included in the analysis of safety and/or efficacy data.”
> “BSA involvement (10–20 %, > 20 %)”
> “PASI (≤ 20, > 20)”
> “Race (White, Non-white)”
> “Baseline weight category (<90 kg, ≥ 90 kg)”
> “Baseline BMI category (<30 kg/m2, ≥30 kg/ m2)”
> “Prior use of biologics (yes, no)”
> “Prior use of TYK 2 molecules (yes, no)”
> “Presence of co-morbidities (yes, no; co-morbidities considered include a history of diabetes, cardiovascular diseases, obesity, depression, hypertension, psoriatic arthritis)”

Source: [Alumis STRIDE statistical analysis plan (2023)](https://cdn.clinicaltrials.gov/large-docs/36/NCT05600036/SAP_001.pdf)

Additional sources: [Stein Gold et al. (2026b)](https://pubmed.ncbi.nlm.nih.gov/42954748/); [Lovell et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39395444/)

## Related pages
- [Envudeucitinib (ESK-001): Moderate-to-severe plaque psoriasis](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Terms and abbreviations](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/terms-and-abbreviations.md)
- [Envudeucitinib (ESK-001): Moderate-to-severe plaque psoriasis](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/executive-summary.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Product information and disease description](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/product-information-and-disease-description.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Clinical evidence](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/clinical-evidence.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Economic information and modeling report](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/economics) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/economics.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: References](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/references) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/references.md)
